2Q EARNINGS: Celgene reports higher income on cancer drugs, raises estimates
This article was originally published in Scrip
Celgene credited double-digit sales growth for a pair of drugs and a solid launch of a new blood cancer therapy as it reported better-than-expected profit. The company also raised its earnings forecast for the year.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.